Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX
Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it sold 11 million shares of common stock for $1 per share. Tharimmune’s stock $THAR was down about 6% in trading on Friday morning.
Data startup raises $10M from Amgen and Merck funds: Culmination Bio received $10 million from Amgen Ventures and the Merck Global Health Innovation Fund, it said Thursday. The company is building a database of de-identified patient data sourced from electronic health records and biospecimens that it says can help biopharmas more quickly identify potential patients for clinical research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.